Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.

[1]  N. Gretz,et al.  Striking Increase of Natriuresis by Low-Dose Spironolactone in Congestive Heart Failure Only in Combination With ACE Inhibition: Mechanistic Evidence to Support RALES , 2000, Circulation.

[2]  P. Galuppo,et al.  Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure. , 2000, Cardiovascular research.

[3]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[4]  D. Harrison,et al.  Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. , 2000, Circulation.

[5]  A. Struthers,et al.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. , 2000, Circulation.

[6]  A. Takeshita,et al.  Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. , 2000, Circulation research.

[7]  D. Stewart,et al.  Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. , 1999, Circulation.

[8]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[9]  R. Busse,et al.  Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. , 1999, Circulation.

[10]  D. Harrison,et al.  Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. , 1999, Biochemical and biophysical research communications.

[11]  R Busse,et al.  NO: the primary EDRF. , 1999, Journal of molecular and cellular cardiology.

[12]  H. Drexler,et al.  Endothelial dysfunction in human disease. , 1999, Journal of molecular and cellular cardiology.

[13]  H. Drexler,et al.  Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.

[14]  H. Drexler.  Endothelium as a therapeutic target in heart failure. , 1998, Circulation.

[15]  J. Mehta,et al.  Increased superoxide anion generation and altered vasoreactivity in rabbits on low-potassium diet. , 1998, American journal of physiology. Heart and circulatory physiology.

[16]  A. Omran,et al.  Increased oxidative stress in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[17]  R. Busse,et al.  Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. , 1998, Cardiovascular research.

[18]  H. Drexler,et al.  Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.

[19]  P. Galuppo,et al.  Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. , 1997, Circulation.

[20]  W. Linz,et al.  Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. , 1997, Hypertension.

[21]  R. Busse,et al.  Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. , 1997, Hypertension.

[22]  R. Ferrari,et al.  Aorta and skeletal muscle NO synthase expression in experimental heart failure. , 1996, Journal of molecular and cellular cardiology.

[23]  M. Ushio-Fukai,et al.  p22phox Is a Critical Component of the Superoxide-generating NADH/NADPH Oxidase System and Regulates Angiotensin IIinduced Hypertrophy in Vascular Smooth Muscle Cells* , 1996, The Journal of Biological Chemistry.

[24]  P. Mulder,et al.  Peripheral artery structure and endothelial function in heart failure: effect of ACE inhibition. , 1996, The American journal of physiology.

[25]  K. Pritchard,et al.  Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. , 1996, Circulation research.

[26]  H. Drexler,et al.  Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. , 1995, The American journal of cardiology.

[27]  H. Drexler,et al.  Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. , 1994, Circulation.

[28]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[29]  X. Xu,et al.  Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. , 1994, The American journal of physiology.

[30]  D. Hayoz,et al.  Endothelial function in chronic congestive heart failure. , 1992, The American journal of cardiology.

[31]  H. Drexler,et al.  Endothelial dysfunction of hindquarter resistance vessels in experimental heart failure. , 1992, The American journal of physiology.

[32]  M. A. Plant.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[33]  B. Greenberg,et al.  Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. , 1991, Circulation research.

[34]  T. Rector,et al.  Endothelium‐Dependent Vasodilation Is Attenuated in Patients With Heart Failure , 1991, Circulation.

[35]  J. Belch,et al.  Oxygen free radicals and congestive heart failure. , 1991, British heart journal.

[36]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[37]  S. Whitebread,et al.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. , 1987, The Journal of pharmacology and experimental therapeutics.

[38]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.